Vivos Therapeutics, Inc.

NasdaqCM:VVOS Stock Report

Market Cap: US$16.3m

Vivos Therapeutics Balance Sheet Health

Financial Health criteria checks 4/6

Vivos Therapeutics has a total shareholder equity of $7.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $15.3M and $7.7M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$6.31m
EquityUS$7.67m
Total liabilitiesUS$7.68m
Total assetsUS$15.35m

Recent financial health updates

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Nov 12
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Sep 10
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Apr 25
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Feb 02
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Apr 18
Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Vivos Therapeutics again delays Q2 2022 results

Aug 23

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Jun 29

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

May 21
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

Vivos Therapeutics: First Take After The Broad Market Sell-Off

Mar 06

Financial Position Analysis

Short Term Liabilities: VVOS's short term assets ($7.4M) exceed its short term liabilities ($5.1M).

Long Term Liabilities: VVOS's short term assets ($7.4M) exceed its long term liabilities ($2.6M).


Debt to Equity History and Analysis

Debt Level: VVOS is debt free.

Reducing Debt: VVOS has no debt compared to 5 years ago when its debt to equity ratio was 1752.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VVOS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VVOS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.2% each year


Discover healthy companies